Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2815-2822

  O'Brien, Mary E R ^a   Gaafar, Rabab M ^b   Popat, Sanjay ^a   Grossi, Francesco ^c   Price, Allan ^d   Talbot, Denis C ^e   Cufer, Tanja ^f   Ottensmeier, Christian ^g   Danson, Sarah ^h   Pallis, Athanasios ⁱ   Hasan, Baktiar ⁱ   Van Meerbeeck, Jan P ^j   Baas, Paul ^k  

^a Royal Marsden Foundation Trust   (United Kingdom)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY OF GENOA   (Italy)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f University Clinic   (Slovenia)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h WESTON PARK HOSPITAL   (United Kingdom)

ⁱ EORTC DATA CENTER   (Belgium)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

Bortezomib; Cisplatin; Mesothelioma; PFSR 18

Indexed keywords

BORTEZOMIB; CISPLATIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEURALGIA; NEUROPATHY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PLEURAL PAIN; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VALIDATION PROCESS; VOMITING;

EID: 84881091484     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.008     Document Type: Article

References (18)

1. J. Francart, C. Legrand, R. Sylvester, G.M. Van, J.P. van Meerbeeck, and A. Robert Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma - the EORTC Lung Cancer Group J Clin Oncol 24 2006 3007 3012
2. T. Treasure, L. Lang-Lazdunski, and D. Waller Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study Lancet Oncol 12 2011 763 772
3. L. Lang-Lazdunski, A. Bille, and R. Lal Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma J Thorac Oncol 7 2012 737 743
4. E.R.E. van Thiel, V.F. Surmont, and J.P. van Meerbeeck Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticanc 11 2011 551 560
5. P. Jenkins, R. Milliner, and C. Salmon Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma Eur J Cancer 47 2011 2143 2149
6. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
7. J.P. van Meerbeeck, R. Gaafar, and C. Manegold Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 2005 6881 6889
8. J. Adams, V.J. Palombella, and E.A. Sausville Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 1999 2615 2622
9. D.A. Fennell, A. Chacko, and L. Mutti BCL-2 family regulation by the 20S proteasome inhibitor bortezomib Oncogene 27 2008 1189 1197
10. Y. Wang, A.K. Rishi, and V.T. Puliyappadamba Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines Cancer Chemother Pharmacol 66 2010 455 466
11. A. Sartore-Bianchi, F. Gasparri, and A. Galvani Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma Clin Cancer Res 13 2007 5942 5951
12. D.A. Fennell, C. McDowell, and S. Busacca Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma J Thorac Oncol 7 2012 1466 1470
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. M.J. Byrne, and A.K. Nowak Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 2004 257 260
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. Guideline for good clinical practice E6(R1), 1996. http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf.
16. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, 2003. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3pdf.
17. B. Turnbull The empirical distribution function with arbitrarily grouped, censored and truncated data JRSS-B 38 1976 290 295
18. James R. Anderson, Kevin C. Cain, and Richard D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719